2.55
-0.3(-10.54%)
Currency In USD
| Previous Close | 2.85 |
| Open | 2.88 |
| Day High | 3.22 |
| Day Low | 2.54 |
| 52-Week High | 26.82 |
| 52-Week Low | 1.35 |
| Volume | 2.6M |
| Average Volume | 3.81M |
| Market Cap | 29.03M |
| PE | -0.17 |
| EPS | -15.14 |
| Moving Average 50 Days | 2.15 |
| Moving Average 200 Days | 9.26 |
| Change | -0.3 |
If you invested $1000 in X4 Pharmaceuticals, Inc. (XFOR) since IPO date, it would be worth $1.01 as of August 18, 2025 at a share price of $2.545. Whereas If you bought $1000 worth of X4 Pharmaceuticals, Inc. (XFOR) shares 5 years ago, it would be worth $9.44 as of August 18, 2025 at a share price of $2.545.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
X4 Pharmaceuticals Announces Closing of Upsized $85 Million Private Placement
GlobeNewswire Inc.
Aug 13, 2025 11:00 AM GMT
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of common stock and
X4 Pharmaceuticals Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
GlobeNewswire Inc.
Aug 12, 2025 11:00 AM GMT
$60 million PIPE financing led by Coastlands Capital, Bain Capital Life Sciences and New Enterprise Associates Newly appointed board and management team includes Dr. Adam Craig as Executive Chairman, John Volpone as President and David Kirske as Chie
X4 Pharmaceuticals Presents Positive Phase 2 Chronic Neutropenia Trial Data in Poster Presentations at the 30th Annual Congress of the European Hematology Association (EHA)
GlobeNewswire Inc.
Jun 16, 2025 12:00 PM GMT
Poster #1654 highlights clinically meaningful and durable increases in circulating neutrophils observed with mavorixafor treatment +/- G-CSF over 6-month study Poster #1669 highlights findings that investigators were willing and able to reduce inject